NCT01978483View on ClinicalTrials.gov

Effect of RANKL Inhibition on UV-induced Immunosuppression

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Ultraviolet RaysImmunosuppressionHypersensitivity, DelayedImmune Tolerance/Drug Effects
Interventions
DRUG

Denosumab

RADIATION

UVB exposure

DRUG

Diphenylcyclopropenone

DRUG

Normal Saline

Trial Locations (1)

H2K 4L5

Innovaderm Research Inc., Montreal

Sponsors
All Listed Sponsors
lead

Innovaderm Research Inc.

OTHER